First and second-line therapy of high-risk MDS patients

被引：0
|
作者：
Platzbecker, U. [1 ]
机构：
[1] Uniklin Dresden, Med Klin 1, Dresden, Germany
来源：
ONKOLOGIE | 2013年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：22 / 22
页数：1
相关论文
共 50 条
  • [31] Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia
    Boccia, Ralph
    Cooper, Nichola
    Ghanima, Waleed
    Boxer, Michael A.
    Hill, Quentin A.
    Sholzberg, Michelle
    Tarantino, Michael D.
    Todd, Leslie K.
    Tong, Sandra
    Bussel, James B.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 190 (06) : 933 - 938
  • [32] Quadruple therapy: first- or second-line anti-Helicobacter pylori therapy?
    de Boer, WA
    TREATMENT OF GASTRO-OESOPHAGEAL REFLUX DISEASE AND HELICOBACTER PYLORI INFECTION, 1998, 20 (02): : 43 - 48
  • [33] Second-line treatments for dyslipidemia in patients at risk of cardiovascular disease
    Kondo, Yoshinobu
    Hamai, Junko
    Nezu, Uru
    Shigematsu, Erina
    Kamiko, Kazunari
    Yamazaki, Shunsuke
    Yoshii, Taishi
    Takahashi, Mayumi
    Takano, Tatsuro
    Kawasaki, Satsuki
    Yamada, Masayo
    Yamakawa, Tadashi
    Terauchi, Yasuo
    ENDOCRINE JOURNAL, 2014, 61 (04) : 343 - 351
  • [34] The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients
    Stauder, Reinhard
    ANNALS OF HEMATOLOGY, 2012, 91 (09) : 1333 - 1343
  • [35] The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients
    Reinhard Stauder
    Annals of Hematology, 2012, 91 : 1333 - 1343
  • [36] Effective Alternative for Second-Line Therapy
    不详
    OBESITY FACTS, 2009, 2 (01) : 57 - 57
  • [37] Axitinim believe in Second-Line Therapy
    Roos, Frederik
    AKTUELLE UROLOGIE, 2012, 43 (03) : 135 - 137
  • [38] Second-line therapy for esophageal cancer
    Martin, Mike G.
    Govindan, Ramoswamy
    Morgensztern, Daniel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (06) : 871 - 876
  • [39] Dolutegravir for second-line antiretroviral therapy
    Hamers, Raph L.
    LANCET INFECTIOUS DISEASES, 2019, 19 (03): : 218 - 219
  • [40] Second-line therapy of ovarian carcinoma
    Sevelda, P
    ONKOLOGIE, 2000, 23 (06): : 593 - 596
12345